Eltrombopag/eltrombopag platelet-raising effect and price

Eltrombopag/Eltrombopag is an oral non-peptide thrombopoietin receptor agonist that stimulates platelet production, leading to increased platelet production. One study evaluated the efficacy, safety, and tolerability of eltrombopag 50 mg once daily and explored the efficacy of increasing the dose to 75 mg.

In this Phase III, randomized, double-blind, placebo-controlled study, adults from 63 sites in 23 countries with chronic idiopathic thrombocytopenic purpura (ITP), a platelet count of less than 30,000 per microliter of blood, and one or more prior ITP treatments received standard care plus once-daily eltrombopag 50 mg (n=76) or placebo (n=38) for up to 6 weeks. Patients were randomly assigned to eltrombopag or placebo in a 2:1 ratio using a validated randomization system. After 3 weeks, patients with platelet counts below 50,000/microliter could have the study drug increased to 75 mg. The primary endpoint was the proportion of patients with a platelet count of 50,000/microliter or higher on Day 43. All participants who received at least one dose of a given treatment were included in the analysis.

Study results showed that73 patients in the eltrombopag group and 37 patients in the placebo group were included in the efficacy population and could be evaluated in the Day 43 analysis. Forty-three (59%) eltrombopag-treated patients and 6 (16%) placebo-treated patients had a response (i.e., platelet count >50,000/microliter; odds ratio [OR] 9.61 [95% confidence interval 3.31-27.86]; p<0.0001). Response to eltrombopag compared with placebo was not affected by predefined study stratification variables (baseline platelet count, concomitant ITP medications, and splenectomy status) or the number of prior ITP treatments. Of the 34 patients who had their eltrombopag dose increased in the efficacy analysis, 10 (29%) responded. Platelet counts usually return to baseline within 2 weeks after the end of treatment.

Patients who received eltrombopag had less bleeding than those who received placebo at any time during the study (OR 0.49; [95% CI 0.26-0.89]; p=0.021). The frequency of grade 3-4 adverse events during treatment and those leading to study discontinuation were similar between the two groups.

It is therefore possible that eltrombopag is chronicEffective treatment of thrombocytopenia in patients with ITP. The original drug of Eltrombopag, namely Eltrombopag ethanolamine tablets, is available in various specifications. The most common ones are 25mg 14 tablets and 25mg 28 tablets. The domestic market price is between 2,000 and 4,000 yuan. This drug has been included in Class B medical insurance, but reimbursement is limited by indications, and patients who do not meet the conditions need to bear the cost themselves. In addition, the original drug of eltrombopag is also sold in overseas markets such as Türkiye and India. The price is affected by the exchange rate and is approximately more than 1,000 yuan per box. If you are looking for cheaper drugs, generic drugs are a good choice. The ingredients of these drugs are similar to the original drugs. They are produced by pharmaceutical factories such as Bangladesh Yaopin International, Laos Lucius Pharmaceuticals, and India NATCO. The prices are affordable, about a few hundred yuan per box, but the price may change with the exchange rate.